The company is demonstrably boosted this development of an novel treatment for amyloid heart disease, leveraging the compound. Early patient results indicates significant benefits for patients affected with this debilitating condition. This effort underscores BridgeBio's dedication to managing critical medical demands in the cardiology field. Attr